Gedatolisib's NDA for advanced breast cancer treatment has been accepted by the FDA, with a priority review and a PDUFA date set for July 17, 2026. The drug is intended for HR+/HER2–, PIK3CA wild-type ...
Welcome to Canucks Live. Here we’ll highlight some of the news that drops daily about the Canucks. Come back throughout the ...
Teachers can use a questioning strategy originally from the business world to guide students to confidently develop and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback